Impact of estetrol (E4) on hemostasis, metabolism and bone turnover in postmenopausal women

J Douxfils; U Gaspard; M Taziaux; M Jost; C Bouvy; R A Lobo; W H Utian; J-M Foidart

doi:10.1080/13697137.2022.2139599

Impact of estetrol (E4) on hemostasis, metabolism and bone turnover in postmenopausal women

J Douxfils, U Gaspard, M Taziaux, M Jost, C Bouvy, R A Lobo, W H Utian, J-M Foidart

Résultats de recherche: Contribution à un journal/une revue › Article › Revue par des pairs

Résumé

OBJECTIVE: This study aimed to determine the effects of estetrol (E4) on hemostasis, lipids, carbohydrate metabolism and bone turnover in postmenopausal women.

METHODS: This study was a multicenter, randomized, double-blind placebo-controlled phase 2 trial. Participants ( n = 180, age 43-64 years) received E4 2.5 mg, 5 mg, 10 mg and 15 mg or placebo once daily for 12 weeks. Changes from baseline at week 12 were evaluated versus placebo for hemostasis parameters, sex hormone binding globulin (SHBG), lipids, carbohydrate metabolism and bone markers.

RESULTS: Changes for hemostasis parameters were minimal with a small increase only in the normalized activated protein C sensitivity ratio in the E4 15 mg group versus placebo. SHBG increased in the E4 5 mg, 10 mg and 15 mg groups versus placebo. High-density lipoprotein cholesterol increased in all E4 groups; changes were not consistent for other lipids. Significant decreases versus placebo were seen for insulin resistance (E4 10 mg group), hemoglobin A1c (E4 15 mg group) and type 1 collagen C-terminal telopeptide (E4 10 mg and 15 mg groups). Small decreases in osteocalcin in the E4 5 mg, 10 mg and 15 mg groups were significant versus the increase observed in placebo.

CONCLUSION: E4 had limited impact on hemostasis and potentially beneficial effects on lipids, carbohydrate metabolism and bone turnover.

langue originale	Anglais
Pages (de - à)	55-63
Nombre de pages	9
journal	Climacteric
Volume	26
Numéro de publication	1
Date de mise en ligne précoce	18 nov. 2022
Les DOIs	https://doi.org/10.1080/13697137.2022.2139599
Etat de la publication	Publié - 2023

SDG des Nations Unies

Ce résultat contribue à ou aux Objectifs de développement durable suivants

Accès au document

10.1080/13697137.2022.2139599

Autres fichiers et liens

Lien vers la publication sur Scopus

Clinical Pharmacology Research Group
Douxfils, J., Dogne, J., Musuamba Tshinanu, F., MASEREEL, B., Wieers, G., Haguet, H., RONVAUX, L., Donis, N., Morimont, L., Evrard, J., Siriez, R., Gillot, C., FAVRESSE, J., BOUVY, C., Djokoto, H., Didembourg, M., David, C., Melchionda, S., Maloteau, V., Boucher, A., Devel, P., Modaffari, E., Vandeputte, M., De Messemaeker, A., Decarpentrie, J., Vassart, J. & De Groote, A.
1/04/22 → …
Projet: Axe de recherche
The HIC Project : Evaluation of hormone-induced coagulopathy
Dogne, J., Douxfils, J., Morimont, L., Didembourg, M. & Evrard, J.
1/09/19 → …
Projet: Recherche

Contient cette citation

@article{e2bd409ea2e44d6b96a5a235a0eb902b,

title = "Impact of estetrol (E4) on hemostasis, metabolism and bone turnover in postmenopausal women",

abstract = "OBJECTIVE: This study aimed to determine the effects of estetrol (E4) on hemostasis, lipids, carbohydrate metabolism and bone turnover in postmenopausal women.METHODS: This study was a multicenter, randomized, double-blind placebo-controlled phase 2 trial. Participants ( n = 180, age 43-64 years) received E4 2.5 mg, 5 mg, 10 mg and 15 mg or placebo once daily for 12 weeks. Changes from baseline at week 12 were evaluated versus placebo for hemostasis parameters, sex hormone binding globulin (SHBG), lipids, carbohydrate metabolism and bone markers. RESULTS: Changes for hemostasis parameters were minimal with a small increase only in the normalized activated protein C sensitivity ratio in the E4 15 mg group versus placebo. SHBG increased in the E4 5 mg, 10 mg and 15 mg groups versus placebo. High-density lipoprotein cholesterol increased in all E4 groups; changes were not consistent for other lipids. Significant decreases versus placebo were seen for insulin resistance (E4 10 mg group), hemoglobin A1c (E4 15 mg group) and type 1 collagen C-terminal telopeptide (E4 10 mg and 15 mg groups). Small decreases in osteocalcin in the E4 5 mg, 10 mg and 15 mg groups were significant versus the increase observed in placebo.CONCLUSION: E4 had limited impact on hemostasis and potentially beneficial effects on lipids, carbohydrate metabolism and bone turnover.",

keywords = "activated protein C sensitivity ratio, bone turnover, carbohydrate metabolism, E4, Estetrol, hemostasis, hormone therapy, lipids, menopause",

author = "J Douxfils and U Gaspard and M Taziaux and M Jost and C Bouvy and Lobo, {R A} and Utian, {W H} and J-M Foidart",

note = "Funding Information: The trial was funded by Estetra SRL (subsidiary of Mithra Pharmaceuticals); Walloon region in Belgium [convention N°7492]. The authors wish to thank the investigators in the participating centers for conducting the E4Relief trial [17]. The authors also thank the members of the Donesta Scientific Advisory Boards for their valuable advice. Medical writing support was provided by Jan Egberts, Nazanin Hakimzadeh and Mireille Gerrits at Terminal 4 Communications, Hilversum, The Netherlands. Maud Hennion (Pharmalex Belgium) provided statistical support. Publisher Copyright: {\textcopyright} 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.",

year = "2023",

doi = "10.1080/13697137.2022.2139599",

language = "English",

volume = "26",

pages = "55--63",

journal = "Climacteric",

issn = "1369-7137",

publisher = "Taylor & Francis",

number = "1",

}

TY - JOUR

T1 - Impact of estetrol (E4) on hemostasis, metabolism and bone turnover in postmenopausal women

AU - Douxfils, J

AU - Gaspard, U

AU - Taziaux, M

AU - Jost, M

AU - Bouvy, C

AU - Lobo, R A

AU - Utian, W H

AU - Foidart, J-M

N1 - Funding Information: The trial was funded by Estetra SRL (subsidiary of Mithra Pharmaceuticals); Walloon region in Belgium [convention N°7492]. The authors wish to thank the investigators in the participating centers for conducting the E4Relief trial [17]. The authors also thank the members of the Donesta Scientific Advisory Boards for their valuable advice. Medical writing support was provided by Jan Egberts, Nazanin Hakimzadeh and Mireille Gerrits at Terminal 4 Communications, Hilversum, The Netherlands. Maud Hennion (Pharmalex Belgium) provided statistical support. Publisher Copyright: © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

PY - 2023

Y1 - 2023

N2 - OBJECTIVE: This study aimed to determine the effects of estetrol (E4) on hemostasis, lipids, carbohydrate metabolism and bone turnover in postmenopausal women.METHODS: This study was a multicenter, randomized, double-blind placebo-controlled phase 2 trial. Participants ( n = 180, age 43-64 years) received E4 2.5 mg, 5 mg, 10 mg and 15 mg or placebo once daily for 12 weeks. Changes from baseline at week 12 were evaluated versus placebo for hemostasis parameters, sex hormone binding globulin (SHBG), lipids, carbohydrate metabolism and bone markers. RESULTS: Changes for hemostasis parameters were minimal with a small increase only in the normalized activated protein C sensitivity ratio in the E4 15 mg group versus placebo. SHBG increased in the E4 5 mg, 10 mg and 15 mg groups versus placebo. High-density lipoprotein cholesterol increased in all E4 groups; changes were not consistent for other lipids. Significant decreases versus placebo were seen for insulin resistance (E4 10 mg group), hemoglobin A1c (E4 15 mg group) and type 1 collagen C-terminal telopeptide (E4 10 mg and 15 mg groups). Small decreases in osteocalcin in the E4 5 mg, 10 mg and 15 mg groups were significant versus the increase observed in placebo.CONCLUSION: E4 had limited impact on hemostasis and potentially beneficial effects on lipids, carbohydrate metabolism and bone turnover.

AB - OBJECTIVE: This study aimed to determine the effects of estetrol (E4) on hemostasis, lipids, carbohydrate metabolism and bone turnover in postmenopausal women.METHODS: This study was a multicenter, randomized, double-blind placebo-controlled phase 2 trial. Participants ( n = 180, age 43-64 years) received E4 2.5 mg, 5 mg, 10 mg and 15 mg or placebo once daily for 12 weeks. Changes from baseline at week 12 were evaluated versus placebo for hemostasis parameters, sex hormone binding globulin (SHBG), lipids, carbohydrate metabolism and bone markers. RESULTS: Changes for hemostasis parameters were minimal with a small increase only in the normalized activated protein C sensitivity ratio in the E4 15 mg group versus placebo. SHBG increased in the E4 5 mg, 10 mg and 15 mg groups versus placebo. High-density lipoprotein cholesterol increased in all E4 groups; changes were not consistent for other lipids. Significant decreases versus placebo were seen for insulin resistance (E4 10 mg group), hemoglobin A1c (E4 15 mg group) and type 1 collagen C-terminal telopeptide (E4 10 mg and 15 mg groups). Small decreases in osteocalcin in the E4 5 mg, 10 mg and 15 mg groups were significant versus the increase observed in placebo.CONCLUSION: E4 had limited impact on hemostasis and potentially beneficial effects on lipids, carbohydrate metabolism and bone turnover.

KW - activated protein C sensitivity ratio

KW - bone turnover

KW - carbohydrate metabolism

KW - E4

KW - Estetrol

KW - hemostasis

KW - hormone therapy

KW - lipids

KW - menopause

UR - http://www.scopus.com/inward/record.url?scp=85142287025&partnerID=8YFLogxK

U2 - 10.1080/13697137.2022.2139599

DO - 10.1080/13697137.2022.2139599

M3 - Article

C2 - 36399023

SN - 1369-7137

VL - 26

SP - 55

EP - 63

JO - Climacteric

JF - Climacteric

IS - 1

ER -

Impact of estetrol (E4) on hemostasis, metabolism and bone turnover in postmenopausal women

Résumé

SDG des Nations Unies

Accès au document

Autres fichiers et liens

Empreinte digitale

Projets

Clinical Pharmacology Research Group

The HIC Project : Evaluation of hormone-induced coagulopathy

Contient cette citation